Erratum to: “Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain” [PAIN® 2013;154(10):1910–19]
Title:
Erratum to: “Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain” [PAIN® 2013;154(10):1910–19]
Author:
Sanga, Panna Katz, Nathaniel Polverejan, Elena Wang, Steven Kelly, Kathleen M. Haeussler, Juergen Thipphawong, John
Appeared in:
Pain
Paging:
Volume 155 (2014) nr. 1 pages 1 p.
Year:
2014
Contents:
Publisher:
2013 International Association for the Study of Pain